ClinicalTrials.gg
CompletedNCT05365477Updated Oct 5, 2026Results posted

Empiric Versus Selective Prevention Strategies for Kidney Stone Disease

A Phase 4 interventional study of Empiric Therapy: Diet and Empiric Therapy: Drug in Kidney Stones and Nephrolithiasis, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Vanderbilt University Medical Center · Phase 4, Interventional, and Prevention

How we know

Updated Oct 5, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.

Enrollment
73rd of 165
56 · median 47
Started
2022
with 13 others
Phase 4
13 of 193
1 open now
Registered
133rd of 193
by date
Lead sponsor
7 of 193
Vanderbilt University Medical Center

Among the 193 studies in Kidney Calculi with a site in United States, this one is the 73rd largest by enrollment of the 165 interventional ones that give a count, is one of 14 that started in 2022, is one of 13 in phase 4, and was the 133rd registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Kidney Calculi with a site in United States, or all of them as a file.
02

Study summary

The aims of this study are to 1) Conduct a randomized clinical trial of selective versus empiric diet plus pharmacologic therapy in high-risk stone formers and 2) Determine adverse effects from, and adherence to selective and empiric strategies.

Read the detailed description

Diet and pharmacologic interventions for preventing future kidney stone episodes are effective, however clinical guideline panels disagree on whether clinicians should perform selective therapy: performing 24-hour urine testing to guide choosing interventions to correct abnormal urinary parameters. The alternative strategy is empiric therapy: applying interventions without 24-hour urine testing. While 24-hour urine testing is considered the standard of care by nephrology and urology specialties for higher risk patients, the American College of Physicians does not recommend 24-hour urine testing.

This is a randomized clinical trial of selective versus empiric therapy for patients with presumed idiopathic calcium stone disease, representing >80% of the kidney stone population. The primary outcome is change in urinary supersaturation, which associates with symptomatic stone recurrence. We will recruit patients with presumed idiopathic calcium stone disease with at least 2 stone events within the previous 5 years. Participants will be randomly assigned to empiric diet plus thiazide with potassium citrate daily, or to selective diet plus pharmacologic therapy based on the 24-hour urine abnormalities identified at baseline and adjusted during follow-up. The primary outcomes will be the calculated calcium oxalate and calcium phosphate supersaturations. In addition, we will determine adverse effects from, and adherence to, selective and empiric strategies.

03

Conditions studied

  • Kidney Stones
  • Nephrolithiasis

Keywords

  • Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Two or more symptomatic kidney stone events in the last 5 years
  • Adult

Exclusion criteria

Exclusion Criteria:

  • Medullary sponge kidney or renal tubular acidosis
  • Untreated urinary obstruction
  • Primary hyperparathyroidism
  • Primary hyperoxaluria
  • Pregnancy
  • Inflammatory bowel disease or bowel resection
  • Sarcoidosis
  • Cystinuria
  • Prior stone composition with uric acid, struvite, cystine, carbonate apatite
  • Use of specific medications (thiazides, topiramate, xanthine oxidase inhibitors, citrate, bicarbonate)
  • Chronic kidney disease stage 3 or higher (\<60)
  • Gouty arthritis or 3 gout episodes in 1 year
  • Known allergy to study medications
  • Hypokalemia or hyponatremia at screening.
  • Age \< 18 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    Empiric Therapy

    Diet intervention and drug intervention not based on 24 hour urine results

    Behavioral: Empiric Therapy: Diet · Drug: Empiric Therapy: Drug

  • Experimental
    Selective Therapy

    Diet intervention and drug intervention based on 24 hour urine results

    Behavioral: Selective Therapy: Diet · Drug: Selective Therapy: Drug

Interventions

  • BehavioralEmpiric Therapy: Diet

    Diet: High water intake - at least 2.5 liters daily Reduce sugar-sweetened cola intake to ≤3 cans per week. Reduce salt intake to \<2000mg sodium daily Reduce red meat intake to two 4-ounce portions per week Normal calcium intake: 3 servings of dairy products (or their equivalents) per day Increase vegetable and fruit intake to ≥5 servings per day Reduce oxalate intake to \<100 mg/day

  • DrugEmpiric Therapy: Drug

    Drug(s): indapamide 1.25mg and potassium citrate 15mEq daily.

  • BehavioralSelective Therapy: Diet

    Diet: Volume \<2.5L Increase fluid intake to ≥ 2.5L/d, based on specific urine volume Calcium \>250mg male, \>200mg female Reduce red meat intake to two 4-oz portions/wk; reduce sodium intake to\<2000mg/d, avoid vitamin D + calcium supplements Oxalate \>40mg Reduce dietary oxalate intake to \<100 mg/d; increase fiber intake to 25-35 g/d Citrate \<450mg male, \<550mg female Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d pH\<5.8 Reduce red meat intake to two 4-oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d Uric acid \>800mg male, \>750mg female Reduce red meat intake to two 4- oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d Sodium \>150mmol Reduce sodium intake to \<2000mg/d Sulfate \> 80mEq or urine urea nitrogen \>14g Reduce red meat intake to three 3-4 oz portions/wk; increase fruit and vegetable intake to ≥5 svgs/d

  • DrugSelective Therapy: Drug

    Drug(s): For calcium \>250mg male, \>200mg female: indapamide 1.25mg and potassium chloride 20mEq. At 1 month if persistent, then increase to indapamide 2.5mg and potassium chloride 20mEq. For citrate \<450mg male, \<550mg female: potassium citrate 15mEq BID. At 1 month if persistent, then increase to potassium citrate 30mEq BID. For pH\<5.8: potassium citrate 15mEq BID. At month if persistent, then increase to potassium citrate 30mEq BID. For uric acid \>800mg male, \>750mg female: allopurinol 300mg. If both elevated calcium and low pH: indapamide 1.25mg and potassium citrate 15mEq BID If both elevated calcium and low citrate: indapamide 1.25mg and potassium citrate 15mEq BID

06

What researchers measure

Primary outcomes

  1. Calcium Oxalate Supersaturation

    Calcium oxalate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium oxalate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 6.0 to 10.0. Higher number indicates a higher supersaturation value (e.g., increased calcium oxalate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium oxalate stone risk). When the concentration of calcium and oxalate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).

    Time frame: Assessed at two months

  2. Calcium Phosphate Supersaturation

    Calcium phosphate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium phosphate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 0.5 to 2.0. Higher number indicates a higher supersaturation value (e.g., increased calcium phosphate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium phosphate stone risk). When the concentration of calcium and phosphate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and phosphate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).

    Time frame: Assessed at two months

Secondary outcomes

  1. Uric Acid Supersaturation

    Uric acid supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of uric acid in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is \<1.0. Higher number indicates a higher supersaturation value (e.g., increased uric acid stone risk). When the concentration of uric acid ions in the urine exceeds their solubility limit, especially in the context of urine pH, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).

    Time frame: Assessed at two months

  2. 24hr Urine Parameters

    Urinary calcium, oxalate, citrate, uric acid

    Time frame: Measured at two months

  3. 24hr Urine Volume

    24hr Urine Volume among participants collected at 2 months.

    Time frame: Two months

  4. 24hr Urine Sodium and Potassium

    24hr Urine Sodium and Potassium

    Time frame: Two months

  5. 24hr Urine pH

    24hr Urine pH

    Time frame: Two months

Other outcomes

  1. Patients With Kidney Stone Events

    Participants who have kidney stone events by self report and clinical imaging, if available

    Time frame: Baseline to 2 months

  2. Adverse Events

    Assessment of adverse events - new hypokalemia, hyponatremia, hypomagnesemia, or newly reported symptoms

    Time frame: 2 months

  3. Medication Adherence

    Percentage of pills taken divided by pills prescribed

    Time frame: Baseline to 2 months

07

Results

Posted Oct 5, 2026

Participant flow

Participant flow — Overall Study
MilestoneEmpiric TherapySelective Therapy
Started2927
Completed2218
Not completed79
Withdrew: Lost to follow-up57
Withdrew: Withdrawal by subject11
Withdrew: Adverse event11

Outcome measures

PrimaryCalcium Oxalate Supersaturation

Calcium oxalate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium oxalate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 6.0 to 10.0. Higher number indicates a higher supersaturation value (e.g., increased calcium oxalate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium oxalate stone risk). When the concentration of calcium and oxalate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).

Time frame:
Assessed at two months
Reported as:
Mean · Unitless ratio
Calcium Oxalate Supersaturation
Unitless ratioEmpiric TherapySelective Therapy
Calcium Oxalate Supersaturation4.7 ± 2.95.0 ± 2.9
Statistical analysis
  • Empiric Therapy vs Selective Therapy · Regression, Linear · p = 0.81 · Mean difference (final values): -0.22 · 95% CI -2.1 to 1.6Referent group is empiric therapy
PrimaryCalcium Phosphate Supersaturation

Calcium phosphate supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of calcium phosphate in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is 0.5 to 2.0. Higher number indicates a higher supersaturation value (e.g., increased calcium phosphate stone risk). A lower number indicates a lower supersaturation value (e.g., lower calcium phosphate stone risk). When the concentration of calcium and phosphate ions in the urine exceeds their solubility limit, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and phosphate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).

Time frame:
Assessed at two months
Reported as:
Mean · Unitless ratio
Calcium Phosphate Supersaturation
Unitless ratioEmpiric TherapySelective Therapy
Calcium Phosphate Supersaturation1.3 ± 0.91.4 ± 1.1
Statistical analysis
  • Empiric Therapy vs Selective Therapy · Regression, Linear · p = 0.58 · Median difference (final values): 0.18 · 95% CI -0.47 to 0.83Referent group is empiric therapy
SecondaryUric Acid Supersaturation

Uric acid supersaturation is calculated using an at-home, 24 hour urine collection. The value is calculated based on the EQUIL 2 equation and describes the likelihood of crystallization of uric acid in solution. The test was performed by Litholink (Labcorp, Itasca, IL). The reference interval is \<1.0. Higher number indicates a higher supersaturation value (e.g., increased uric acid stone risk). When the concentration of uric acid ions in the urine exceeds their solubility limit, especially in the context of urine pH, the urine becomes supersaturated, which can lead to spontaneous precipitation of minerals and the formation of crystal nuclei. The measure is a unitless ratio because it is calculated by dividing the concentration product of calcium and oxalate ions in a fluid by their thermodynamic solubility product constant (both numerator and denominator have the same units).

Time frame:
Assessed at two months
Reported as:
Mean · Unitless ratio
Uric Acid Supersaturation
Unitless ratioEmpiric TherapySelective Therapy
Uric Acid Supersaturation0.6 ± 0.60.7 ± 0.8
Secondary24hr Urine Parameters

Urinary calcium, oxalate, citrate, uric acid

Time frame:
Measured at two months
Reported as:
Mean · mg/d
24hr Urine Parameters
mg/dEmpiric TherapySelective Therapy
Calcium177 ± 100226 ± 151
Oxalate35 ± 1938 ± 15
Citrate607 ± 261797 ± 452
Uric acid775 ± 325742 ± 359
Secondary24hr Urine Volume

24hr Urine Volume among participants collected at 2 months.

Time frame:
Two months
Reported as:
Mean · Liters
24hr Urine Volume
LitersEmpiric TherapySelective Therapy
24hr Urine Volume2.1 ± 0.82.2 ± 0.9
Secondary24hr Urine Sodium and Potassium

24hr Urine Sodium and Potassium

Time frame:
Two months
Reported as:
Mean · mmol
24hr Urine Sodium and Potassium
mmolEmpiric TherapySelective Therapy
Sodium173 ± 95195 ± 104
Potassium75 ± 3187 ± 35
Secondary24hr Urine pH

24hr Urine pH

Time frame:
Two months
Reported as:
Mean · pH units
24hr Urine pH
pH unitsEmpiric TherapySelective Therapy
24hr Urine pH6.4 ± 0.46.5 ± 0.5
Other pre-specifiedPatients With Kidney Stone Events

Participants who have kidney stone events by self report and clinical imaging, if available

Time frame:
Baseline to 2 months
Reported as:
Count of participants · Participants
Patients With Kidney Stone Events
ParticipantsEmpiric TherapySelective Therapy
Patients With Kidney Stone Events21
Other pre-specifiedAdverse Events

Assessment of adverse events - new hypokalemia, hyponatremia, hypomagnesemia, or newly reported symptoms

Time frame:
2 months
Reported as:
Number · participants
Adverse Events
participantsEmpiric TherapySelective Therapy
Hypokalemia21
Hyponatremia00
General symptoms03
Neurologic/musculoskeletal22
Skin00
Ear/nose/mouth20
Respiratory10
Cardiac00
Gastrointestinal135
Urinary21
Psychiatric00
Any other concern00
Side effect-induced treatment change02
Other pre-specifiedMedication Adherence

Percentage of pills taken divided by pills prescribed

Time frame:
Baseline to 2 months
Reported as:
Mean · percentage of pills taken
Medication Adherence
percentage of pills takenEmpiric TherapySelective Therapy
Medication Adherence98 ± 397 ± 3

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empiric Therapy0/22 (0%)0/22 (0%)13/22 (59.1%)
Selective Therapy0/18 (0%)0/18 (0%)5/18 (27.8%)
Most frequent other events
Most frequent other events
EventEmpiric TherapySelective Therapy
Gastrointestial side effectsGastrointestinal disorders13/225/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Empiric TherapySelective TherapyTotal
Mean41.4 (26.4 to 53.8)44.7 (37.2 to 56.5)44.5 (36.1 to 54.3)
Sex: Female, Male
Sex: Female, Male(Participants)Empiric TherapySelective TherapyTotal
Female161430
Male131326
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Empiric TherapySelective TherapyTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American101
White252752
More than one race000
Unknown or Not Reported101
BMI
BMI(kg/m^2)Empiric TherapySelective TherapyTotal
Mean30 ± 5.831 ± 8.031 ± 6.9
08

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
09

References and documents

Publications

  • Widmer A, Lee A, Koyama T, Goldfarb DS, Hsi RS, Silver HJ. Targeted versus empiric approach for prevention of recurrent kidney stones: Insights on diet therapy from a randomized trial. Clin Nutr. 2026 Aug 11;65:106754. doi: 10.1016/j.clnu.2026.106754. Online ahead of print. PubMed 42617398 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Sep 2025, 37 months.

Results were first posted in Oct 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 9, 2022
StartActual
Aug 4, 2022
Primary completionActual
Sep 26, 2025
CompletionActual
Mar 31, 2026
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 5, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedCalcium oxalate supersaturationOxalate SupersaturationTime frame: Baseline compared to two months → Assessed at two months
  • EditedCalcium phosphate supersaturationPhosphate SupersaturationTime frame: Baseline compared to two months → Assessed at two months
Oct 5, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42617398 ↗
Oct 5, 2026
Secondary outcomes
5 edited, 3 added, 3 removed
What changed in the outcomes
  • EditedUric acid supersaturationAcid SupersaturationTime frame: Baseline compared to two months → Assessed at two months
  • Edited24hr urine parametersUrine ParametersTime frame: Baseline compared to two months → Measured at two months
  • Added24hr Urine VolumeTime frame: Two months
  • Added24hr Urine Sodium and PotassiumTime frame: Two months
  • Added24hr Urine pHTime frame: Two months
  • Editedother outcomePatients With Kidney stone eventsStone EventsTime frame: Baseline to 2 months
  • Editedother outcomeAdverse eventsEventsTime frame: Baseline to 2 months → 2 months
  • Editedother outcomeDiet adherenceMedication AdherenceTime frame: Baseline to 2 months
  • Removedother outcome24hr urine parameters from baseline to month 1Time frame: Baseline to 1 month
  • Removedother outcome24hr urine parameters from month 1 to month 2Time frame: 1 month to 2 months
  • Removedother outcomeMedication adherenceTime frame: Baseline to 2 months
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42617398 ↗
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedCalcium oxalate supersaturationOxalate SupersaturationTime frame: Baseline compared to two months → Assessed at two months
    • EditedCalcium phosphate supersaturationPhosphate SupersaturationTime frame: Baseline compared to two months → Assessed at two months
    Secondary outcomes 5 edited, 3 added, 3 removed
    What changed in the outcomes
    • EditedUric acid supersaturationAcid SupersaturationTime frame: Baseline compared to two months → Assessed at two months
    • Edited24hr urine parametersUrine ParametersTime frame: Baseline compared to two months → Measured at two months
    • Added24hr Urine VolumeTime frame: Two months
    • Added24hr Urine Sodium and PotassiumTime frame: Two months
    • Added24hr Urine pHTime frame: Two months
    • Editedother outcomePatients With Kidney stone eventsStone EventsTime frame: Baseline to 2 months
    • Editedother outcomeAdverse eventsEventsTime frame: Baseline to 2 months → 2 months
    • Editedother outcomeDiet adherenceMedication AdherenceTime frame: Baseline to 2 months
    • Removedother outcome24hr urine parameters from baseline to month 1Time frame: Baseline to 1 month
    • Removedother outcome24hr urine parameters from month 1 to month 2Time frame: 1 month to 2 months
    • Removedother outcomeMedication adherenceTime frame: Baseline to 2 months
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05365477
Responsible party
David Penson (Professor and Chair, Department of Urology, Vanderbilt University Medical Center) — Principal investigator
First posted
May 9, 2022
Start date
Aug 4, 2022
Primary completion
Sep 26, 2025
Completion
Mar 31, 2026
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Study contacts

Ryan Hsi, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion